Assembly Biosciences (ASMB) Coverage Initiated at B. Riley
Analysts at B. Riley started coverage on shares of Assembly Biosciences (NASDAQ:ASMB) in a research note issued to investors on Friday. The brokerage set a “neutral” rating and a $35.00 price target on the biopharmaceutical company’s stock. B. Riley’s target price points to a potential downside of 22.07% from the stock’s current price.
Several other equities research analysts have also recently commented on ASMB. Chardan Capital reissued a “buy” rating on shares of Assembly Biosciences in a report on Sunday, September 17th. Zacks Investment Research raised Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. Jefferies Group assumed coverage on Assembly Biosciences in a report on Wednesday, November 8th. They set a “buy” rating and a $50.00 target price on the stock. BidaskClub cut Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. Finally, ValuEngine cut Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $39.25.
Shares of Assembly Biosciences (NASDAQ ASMB) opened at $44.91 on Friday. The firm has a market capitalization of $920.98, a P/E ratio of -15.12 and a beta of 0.91. Assembly Biosciences has a twelve month low of $12.15 and a twelve month high of $52.37.
Several hedge funds and other institutional investors have recently bought and sold shares of ASMB. Perceptive Advisors LLC bought a new position in shares of Assembly Biosciences in the fourth quarter valued at $8,679,000. Baker BROS. Advisors LP bought a new position in shares of Assembly Biosciences in the third quarter valued at $1,803,000. State Street Corp bought a new position in shares of Assembly Biosciences in the second quarter valued at $4,234,000. JPMorgan Chase & Co. bought a new position in shares of Assembly Biosciences in the second quarter valued at $3,426,000. Finally, Valeo Financial Advisors LLC purchased a new position in Assembly Biosciences during the 3rd quarter worth approximately $4,963,000. 62.00% of the stock is currently owned by institutional investors.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.